International Clinical Trial: Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07813637) titled 'Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC' on Sept. 4.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Janux Therapeutics

Condition: Prostate Cancer Castration-Resistant Prostate Cancer (CRPC) Metastatic Prostate Cancer Metastatic Castration-Resistant Prostate Cancer Patients

Intervention: Drug: JANX013 Drug: JANX007 Drug: JANX013

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: September 2026

Target Sample Size: 110

T...